119 related articles for article (PubMed ID: 16862579)
21. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
Mounayar S; Boulet S; Tandé D; Jan C; Pessiglione M; Hirsch EC; Féger J; Savasta M; François C; Tremblay L
Brain; 2007 Nov; 130(Pt 11):2898-914. PubMed ID: 17855373
[TBL] [Abstract][Full Text] [Related]
22. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
24. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
25. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
Blandini F; Levandis G; Bazzini E; Nappi G; Armentero MT
Eur J Neurosci; 2007 Jan; 25(2):397-405. PubMed ID: 17284180
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
[TBL] [Abstract][Full Text] [Related]
27. Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease.
Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Exp Neurol; 2008 Aug; 212(2):548-51. PubMed ID: 18508049
[TBL] [Abstract][Full Text] [Related]
28. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
[TBL] [Abstract][Full Text] [Related]
29. Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: implications for Parkinson's disease.
Fitzgerald P; Mandel A; Bolton AE; Sullivan AM; Nolan Y
Behav Brain Res; 2008 Dec; 195(2):271-4. PubMed ID: 18817814
[TBL] [Abstract][Full Text] [Related]
30. Alpha-synuclein overexpression model.
Mochizuki H; Yamada M; Mizuno Y
J Neural Transm Suppl; 2006; (70):281-4. PubMed ID: 17017543
[TBL] [Abstract][Full Text] [Related]
31. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.
Mathur BN; Neely MD; Dyllick-Brenzinger M; Tandon A; Deutch AY
Brain Res; 2007 Sep; 1168():83-9. PubMed ID: 17706185
[TBL] [Abstract][Full Text] [Related]
32. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
[TBL] [Abstract][Full Text] [Related]
33. Systemic proteasomal inhibitor exposure enhances dopamine turnover and decreases dopamine levels but does not affect MPTP-induced striatal dopamine depletion in mice.
Hirst SJ; Ferger B
Synapse; 2008 Feb; 62(2):85-90. PubMed ID: 17992685
[TBL] [Abstract][Full Text] [Related]
34. No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism.
Halliday G; Herrero MT; Murphy K; McCann H; Ros-Bernal F; Barcia C; Mori H; Blesa FJ; Obeso JA
Mov Disord; 2009 Jul; 24(10):1519-23. PubMed ID: 19526568
[TBL] [Abstract][Full Text] [Related]
35. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
[TBL] [Abstract][Full Text] [Related]
36. Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease.
Ebert AD; Beres AJ; Barber AE; Svendsen CN
Exp Neurol; 2008 Jan; 209(1):213-23. PubMed ID: 18061591
[TBL] [Abstract][Full Text] [Related]
37. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
38. The influence of the subthalamic nucleus upon the damage to the dopamine system following lesions of globus pallidus in rats.
Wright AK; Arbuthnott GW
Eur J Neurosci; 2007 Aug; 26(3):642-8. PubMed ID: 17634067
[TBL] [Abstract][Full Text] [Related]
39. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
40. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats].
Wang S; Qi XJ; Han D
Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
